RAIN Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
$8.55 +0.05 (0.59%)
As of 03/27/2023 14:14:20 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 04/23/2021
Outstanding shares: 36,356,233
Average volume: 230,281
Market cap: $313,754,291
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: BN2RM92
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%